The world is changing fast and to keep up you need local knowledge with global context.
The “drug jointly developed with Ridgeback Biotherapeutics cut risk of hospitalization or death by 50% in early look at progress.”
Professor Colleen Aldous looks at the negative narrative developing around the use of Ivermectin in Covid-19 treatment that the mainstream media is perpetuating.
BizNews community member Kin Bentley shares his frustrations with censorship around Covid-19 – and suggests a possible solution.
Shionogi has started human trials for a once-a-day pill designed to neutralise Covid-19 in less than a week, reports The Wall Street Journal.
The cheap generic drug which many believe helps fight the coronavirus is once more in the spotlight, with this note opening a new avenue of inquiry for the open minded.
This synopsis by Rubin van Niekerk is on Bryant’s peer reviewed meta analysis about 60 studies on the treatment impact of Ivermectin on Covid-19.
Rebecca Giersiefen looks at ivermectin as a Covid treatment, asking why so many institutions haven’t authorised its use – despite evidence of its efficacy.
Ivermectin is seen as a repeat of hydroxychloroquine and not to be taken seriously. Belief in it, worthy only of derision, writes Andrew Bannister.
‘Executives at Moderna, Merck are among those who have reaped the biggest rewards’, reports Inti Pacheco of The Wall Street Journal.
In the new world, the value of transparent and honest communication is priceless. Businesses which fail to recognise this are going to lose big.